Decreased microRNA‑768‑3p expression indicates a poor prognosis in patients with breast cancer and promotes breast cancer cell viability, migration and invasion

Zhou,Yanhua; Wang,Ying; Wang,Lili; Zhang,Jing; Liu,Xin

doi:10.3892/ol.2021.12840

Decreased microRNA‑768‑3p expression indicates a poor prognosis in patients with breast cancer and promotes breast cancer cell viability, migration and invasion

Authors:
- Yanhua Zhou
- Ying Wang
- Lili Wang
- Jing Zhang
- Xin Liu
View Affiliations

Affiliations: Department of Oncology, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261031, P.R. China, Department of Quality Control Division, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261031, P.R. China, Department of Operating Room, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261031, P.R. China
Published online on: June 2, 2021 https://doi.org/10.3892/ol.2021.12840
Article Number: 579
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is the most common malignancy in women and microRNA‑768‑3p (miR‑768‑3p) is abnormally expressed in hepatocellular carcinoma, non‑small cell lung carcinomas and melanoma. The aim of the present study was to evaluate the prognostic value and biological function of miR‑768‑3p in breast cancer. The expression of miR‑768‑3p in tumor tissues and adjacent tissues of 116 patients with breast cancer obtained by surgery and normal breast cell lines MCF‑10A and breast cancer cell lines (MCF‑7, MDA‑MB‑231, T‑47D and SK‑BR‑3) were detected by reverse transcription‑quantitative PCR. The association between miR‑768‑3p expression and the clinicopathological characteristics of patients was analyzed using the χ² test. In addition, the Kaplan‑Meier method was used for survival analysis. A Cox regression model was used to examine the effect of miR‑768‑3p on the prognosis of patients with breast cancer. Hemocytometer cell counting and Transwell assays were used to detect the effects of miR‑768‑3p on the characteristics of breast cancer cells. The target genes of miR‑768‑3p in breast cancer were identified by bioinformatics software and detected by luciferase reporter assay. Compared with normal tissues and normal breast cancer cells, miR‑768‑3p was significantly decreased in breast cancer tissues and cancer cells (P<0.001). The reduction in miR‑768‑3p was significantly associated with lymph node metastasis (P=0.040), Tumor Node Metastasis stage (P=0.035), and cancer subtype (P=0.008). In addition, patients with low miR‑768‑3p expression had a shorter overall survival time (log‑rank P=0.022) compared with those with high expression and miR‑768‑3p may be a potential prognostic marker (hazard ratio=4.637; 95% confidence interval=1.296‑16.597; P=0.018). When transfected with miR‑768‑3p inhibitor, cell viability, migration and invasion were significantly promoted compared with the control group (P<0.05). In addition, eukaryotic translation initiation factor 4E (eIF4E) was the target gene of miR‑768‑3p in breast cancer. All experiments confirmed that miR‑768‑3p, a tumor suppressor, inhibited the viability, migration and invasion of breast cancer cells through eIF4E. miR‑768‑3p may be a potential prognostic marker of breast cancer and may participate in the progression of breast cancer.

View Figures

View References

1	Guo R, Chen Y, Borgard H, Jijiwa M, Nasu M, He M and Deng Y: The function and mechanism of lipid molecules and their roles in the diagnosis and prognosis of breast cancer. Molecules. 25:48642020. View Article : Google Scholar : PubMed/NCBI
2	Gu Y, Wu G, Zou X, Huang P and Yi L: Prognostic value of site-specific metastases and surgery in de novo stage IV triple-negative breast cancer: A population-based analysis. Med Sci Monit. 26:e9204322020. View Article : Google Scholar : PubMed/NCBI
3	Wang M, Ji S, Shao G, Zhang J, Zhao K, Wang Z and Wu A: Effect of exosome biomarkers for diagnosis and prognosis of breast cancer patients. Clin Transl Oncol. 20:906–911. 2018. View Article : Google Scholar : PubMed/NCBI
4	Li RH, Chen M, Liu J, Shao CC, Guo CP, Wei XL, Li YC, Huang WH and Zhang GJ: Long noncoding RNA ATB promotes the epithelial-mesenchymal transition by upregulating the miR-200c/Twist1 axe and predicts poor prognosis in breast cancer. Cell Death Dis. 9:11712018. View Article : Google Scholar : PubMed/NCBI
5	Su M, Niu Y, Dang Q, Qu J, Zhu D, Tang Z and Gou D: Circulating microRNA profiles based on direct S-Poly(T)Plus assay for detection of coronary heart disease. J Cell Mol Med. 24:5984–5997. 2020. View Article : Google Scholar : PubMed/NCBI
6	Xiao Y, Humphries B, Yang C and Wang Z: miR-205 dysregulations in breast cancer: The Complexity and Opportunities. Noncoding RNA. 5:532019.PubMed/NCBI
7	Chong ZX, Yeap SK and Ho WY: Dysregulation of miR-638 in the progression of cancers. Pathol Res Pract. Jan 29–2021.(Online ahead of print). View Article : Google Scholar
8	Cai H, Lin H, Cao W, Sun J, Huang Y and Fang Y: Downregulation of miR-519a predicts poor prognosis and contributes to tumor progression in gastric cancer. Oncol Res Treat. 43:19–26. 2020. View Article : Google Scholar : PubMed/NCBI
9	Peng P, Chen T, Wang Q, Zhang Y, Zheng F, Huang S, Tang Y, Yang C, Ding W, Ren D, et al: Decreased miR-218-5p levels as a serum biomarker in bone metastasis of prostate cancer. Oncol Res Treat. 42:165–185. 2019. View Article : Google Scholar : PubMed/NCBI
10	Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, Wang JF, Zhang Z, Lu S, Huang X, et al: Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol. 29:4781–4788. 2011. View Article : Google Scholar : PubMed/NCBI
11	Petric R, Gazic B, Goricar K, Dolzan V, Dzodic R and Besic N: Expression of miRNA and occurrence of distant metastases in patients with hurthle cell carcinoma. Int J Endocrinol. 2016:89452472016. View Article : Google Scholar : PubMed/NCBI
12	Xie Z, Chen W, Chen Y, Wang X, Gao W and Liu Y: miR-768-3p is involved in the viability, invasion and migration of non-small cell lung carcinomas. Int J Oncol. 51:1574–1582. 2017. View Article : Google Scholar : PubMed/NCBI
13	Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D and Wang Y: Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol. 24:652–657. 2009. View Article : Google Scholar : PubMed/NCBI
14	Zheng T, Zhang X, Wang Y and Yu X: Predicting associations between microRNAs and target genes in breast cancer by bioinformatics analyses. Oncol Lett. 12:1067–1073. 2016. View Article : Google Scholar : PubMed/NCBI
15	Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Zhang P, Fan C, Du J, Mo X and Zhao Q: Association of miR-1247-5p expression with clinicopathological parameters and prognosis in breast cancer. Int J Exp Pathol. 99:199–205. 2018. View Article : Google Scholar : PubMed/NCBI
18	Fahad Ullah M: Breast cancer: Current perspectives on the disease status. Adv Exp Med Biol. 1152:51–64. 2019. View Article : Google Scholar : PubMed/NCBI
19	Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD and Feuer EJ; Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators, : Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 353:1784–1792. 2005. View Article : Google Scholar : PubMed/NCBI
20	Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010. View Article : Google Scholar : PubMed/NCBI
21	Zhou W, Gong J, Chen Y, Chen J, Zhuang Q, Cao J, Mei Z and Hu B: Long noncoding RNA LINC00899 suppresses breast cancer progression by inhibiting miR-425. Aging (Albany NY). 11:10144–10153. 2019. View Article : Google Scholar : PubMed/NCBI
22	Rahman MM, Brane AC and Tollefsbol TO: MicroRNAs and epigenetics strategies to reverse breast cancer. Cells. 8:12142019. View Article : Google Scholar : PubMed/NCBI
23	Weng YS, Tseng HY, Chen YA, Shen PC, Al Haq AT, Chen LM, Tung YC and Hsu HL: MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer. Mol Cancer. 18:422019. View Article : Google Scholar : PubMed/NCBI
24	Fang H, Jiang W, Jing Z, Mu X and Xiong Z: miR-937 regulates the viability and apoptosis via targeting APAF1 in breast cancer. Onco Targets Ther. 12:5687–5699. 2019. View Article : Google Scholar : PubMed/NCBI
25	Li F: Expression of miR-221 and miR-489 in breast cancer patients and their relationship with prognosis. Oncol Lett. 19:1523–1529. 2020.PubMed/NCBI
26	Sun R, Muheremu A and Hu Y: miRNA-30c can be used as a target in the diagnosis and treatment of osteosarcoma. Onco Targets Ther. 11:9091–9099. 2018. View Article : Google Scholar : PubMed/NCBI
27	Wang F, Dai M, Chen H, Li Y, Zhang J, Zou Z and Yang H: Prognostic value of hsa-mir-299 and hsa-mir-7706 in hepatocellular carcinoma. Oncol Lett. 16:815–820. 2018.PubMed/NCBI
28	Li C, Zhang J, Ma Z, Zhang F and Yu W: miR-19b serves as a prognostic biomarker of breast cancer and promotes tumor progression through PI3K/AKT signaling pathway. Onco Targets Ther. 11:4087–4095. 2018. View Article : Google Scholar : PubMed/NCBI
29	Quan Y, Huang X and Quan X: Expression of miRNA-206 and miRNA-145 in breast cancer and correlation with prognosis. Oncol Lett. 16:6638–6642. 2018.PubMed/NCBI
30	Vriens MR, Weng J, Suh I, Huynh N, Guerrero MA, Shen WT, Duh QY, Clark OH and Kebebew E: MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. Cancer. 118:3426–3432. 2012. View Article : Google Scholar : PubMed/NCBI
31	Jiang CC, Croft A, Tseng HY, Guo ST, Jin L, Hersey P and Zhang XD: Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma. Oncogene. 33:2577–2588. 2014. View Article : Google Scholar : PubMed/NCBI
32	Pisera A, Campo A and Campo S: Structure and functions of the translation initiation factor eIF4E and its role in cancer development and treatment. J Genet Genomics. 45:13–24. 2018. View Article : Google Scholar : PubMed/NCBI
33	Ma X, Li B, Liu J, Fu Y and Luo Y: Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E. J Exp Clin Cancer Res. 38:662019. View Article : Google Scholar : PubMed/NCBI
34	Wu S, Yang L, Wu D, Gao Z, Li P, Huang W and Wang X: AEG-1 induces gastric cancer metastasis by upregulation of eIF4E expression. J Cell Mol Med. 21:3481–3493. 2017. View Article : Google Scholar : PubMed/NCBI
35	Jin J, Xiang W, Wu S, Wang M, Xiao M and Deng A: Targeting eIF4E signaling with ribavirin as a sensitizing strategy for ovarian cancer. Biochem Biophys Res Commun. 510:580–586. 2019. View Article : Google Scholar : PubMed/NCBI
36	Zhao Y, Yan M, Yun Y, Zhang J, Zhang R, Li Y, Wu X, Liu Q, Miao W and Jiang H: MicroRNA-455-3p functions as a tumor suppressor by targeting eIF4E in prostate cancer. Oncol Rep. 37:2449–2458. 2017. View Article : Google Scholar : PubMed/NCBI
37	Liu F, Wang X, Li J, Gu K, Lv L, Zhang S, Che D, Cao J, Jin S and Yu Y: miR-34c-3p functions as a tumour suppressor by inhibiting eIF4E expression in non-small cell lung cancer. Cell Prolif. 48:582–592. 2015. View Article : Google Scholar : PubMed/NCBI
38	Karaki S, Andrieu C, Ziouziou H and Rocchi P: The eukaryotic translation initiation Factor 4E (eIF4E) as a therapeutic target for cancer. Adv Protein Chem Struct Biol. 101:1–26. 2015. View Article : Google Scholar : PubMed/NCBI
39	Sobocan M, Smolle MA, Schatz C and Haybaeck J: The interplay of tumor stroma and translational factors in endometrial cancer. Cancers (Basel). 12:20742020. View Article : Google Scholar : PubMed/NCBI